Maddi Hebebrand, MC, Associate Editor

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

Find out what the top 10 most popular articles of 2024 were from Dermatology Times.

Catch up on Dermatology Times conference coverage from July through December of this year.

Catch up on coverage of FDA-approved drugs in the second half of 2024.

Catch up on Dermatology Times conference coverage from January through June of this year.

Catch up on coverage of FDA-approved drugs in the first half of 2024.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

Deucravacitinib achieved ACR20 response in patients with PsA at week 16, with a safety profile consistent with previous studies.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

Hawkes shared his excitement for the near future of dermatology, recognizing the increasing ability to provide tailored care to patients.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role of patient education.

Click here to answer today's poll and read more about practice management around the holiday season.

A recent review recognized the aesthetic concerns associated with GLP-1-induced weight loss and noted treatment options for various challenges.

Swanson and Lockshin explored how PDE4 inhibitors improve quality of life for AD patients through targeted treatments that address both inflammation and chronic symptoms.

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

The review found AD can disrupt family life, as caregiving responsibilities can lead to stress, guilt, and reduced opportunities for shared activities.

Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

Researchers stated that therapy represents a “valuable nonpharmacological intervention that offers an innovative therapeutic alternative” for acne treatment.

Researchers found integrating dermatologists into primary care reduces costs and improves diagnostic precision for skin conditions.

Researchers found patients treated with risankizumab had higher rates of skin clearance and greater improvement than those treated with deucravacitinib.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.